aclidinium vs dupilumab
Side-by-side comparison of aclidinium and dupilumab Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Dupixent
Duaklir Pressair is a combination medicine used to help people with COPD breathe better. It contains two medicines that open up the airways in your lungs.
Dupixent is a medicine that can help treat several conditions. It works by blocking certain proteins in your body that cause inflammation.
Duaklir Pressair is used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. This medicine helps to open the airways and make it easier to breathe for people with COPD.
Dupixent can treat moderate-to-severe atopic dermatitis (eczema) in adults and children 6 months and older. It is also used for asthma in people 6 years and older, especially if they have an eosinophilic phenotype or need oral steroids. Dupixent can also treat chronic rhinosinusitis with nasal polyps in adults and children 12 years and older, eosinophilic esophagitis in adults and children 1 year and older, prurigo nodularis and chronic spontaneous urticaria in adults and children 12 years and older, chronic obstructive pulmonary disease in adults, and bullous pemphigoid in adults.
Duaklir Pressair contains two medicines that work in different ways. One medicine relaxes the muscles around your airways, opening them up. The other medicine prevents the muscles from tightening.
Dupixent is a type of medicine called a monoclonal antibody. It blocks two proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13). By blocking these proteins, Dupixent helps to reduce inflammation and improve your symptoms.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Injection site reactions (like redness, swelling, or pain)
- • Conjunctivitis (pink eye)
- • Blepharitis (eyelid inflammation)
- • Oral herpes (cold sores)
- • Keratitis (inflammation of the cornea)
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Itching 48,441
- Eczema 37,675
- Using the medicine for a condition it's not approved for 36,010
- Skin rash 33,431
- Pain at the injection site 30,477
LABAs, such as formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, increase the risk of asthma-related death. Duaklir Pressair is not for asthma. Do not use Duaklir Pressair if you are allergic to milk proteins or any of the ingredients in it. Tell your doctor if you have heart problems, glaucoma, trouble urinating, diabetes, or seizures.
Dupixent can cause serious allergic reactions, including anaphylaxis. Stop using Dupixent and get medical help right away if you have any signs of an allergic reaction. Tell your doctor if you get new or worsening eye problems, such as conjunctivitis or keratitis. Dupixent can sometimes cause eosinophilic conditions, so watch for symptoms like a vasculitic rash, worsening lung symptoms, heart problems, kidney problems, or nerve damage. Do not stop taking steroid medicines suddenly when you start Dupixent. Talk to your doctor about how to slowly lower your steroid dose if needed. Tell your doctor if you develop new psoriasis symptoms or joint symptoms.
It is not known if Duaklir Pressair will harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if this medicine passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Duaklir Pressair.
Tell your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry to track outcomes in women who use Dupixent during pregnancy; you can enroll by calling 1-877-311-8972. It is not known if Dupixent passes into breast milk or if it could harm a nursing baby, so talk to your doctor about the best way to feed your baby if you are using Dupixent.
Also Compare — Nearby Drugs
Compare aclidinium with
How to Read This aclidinium vs dupilumab Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while dupilumab sits within the Anti-IL-4/IL-13 Monoclonal Antibody class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while dupilumab has 186,034. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aclidinium and dupilumab — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.